Study details
Enrolling now
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT IDNCT05169970ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
215
Study length
about 5.1 years
Ages
18+
Sex
Male only
Locations
7 sites in NJ, NY
About this study
This trial is testing whether stereotactic body radiation therapy (SBRT) without androgen deprivation therapy (ADT) can prevent prostate cancer from coming back or spreading. The researchers will also examine how safe and effective it is to use Decipher test results to determine which patients need more extensive radiation treatments.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Stereotactic Body Radiation Therapy (SBRT)
PhasePhase 2
Primary goalRate of biochemical progression free survival
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low6%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Rate of biochemical progression free survival
Body systems
Oncology